- Church Of Scientology Celebrates A Decade Of Expansion Under The Leadership Of David Miscavige
- Here's Why the Microsoft Surface Pro 4 Is Better Than the iPad Pro
- Would a Mitt Romney Presidency Be Good for the FinTech Industry?
- Tesla Motors Stock Will Sell Off Into 2016 but then Stage a Huge Rally to $500
- DraftKings, FanDuel Players Fight Repayment of Credit-Card Bets
The FDA is highly critical of BioMarin Pharmaceuticals' drisapersen, concluding that efficacy data from three clinical trials do 'not reach the level of substantial evidence' necessary for approval.
Sick of watching those scary, sad drug ads during the game? So is the American Medical Association.
Stocks ended the Thursday trading day little changed after a surge in tech names balanced out a selloff in health care.
Stocks worldwide did not move significantly in the wake of Friday’s tragic Paris attacks.
Estee Lauder’s (EL) cosmetics may see a huge sales spike on Black Friday, but investors are better off looking at the company over the long term than a single day.
U.S. stocks opened mixed Thursday as weekly initial jobless claims fell 5,000 compared to last week and coming in almost exactly as economists had predicted at 271,000.
Square (SQ), the mobile payment processing company, has fallen short on pricing its IPO.
'Tis the season for Amazon to shine as Cyber Monday and the holiday shopping season approach.
Tis the season for Amazon (AMZN) to shine as Cyber-Monday and the Christmas shopping season approach.
Innovative biotechnology companies want to focus on their research and many are outsourcing the administrative side to P R A Healthcare.
Looking for fat dividends in a yield-hungry market? Mattel, Sun Life Financial and Johnson & Johnson are trading at compelling valuations as Thanksgiving approaches.
The pharmaceutical giant has been under scrutiny for its pricing and distribution practices, but the company may offer a good investment opportunity for investors who can stomach some risk.
When it comes to investing in health care, hedge fund pro John Paulson knows his stuff.
On Nov. 24, a panel of outside experts convened by the U.S. Food and Drug Administration is set to review drisapersen, BioMarin's experimental drug for Duchenne muscular dystrophy.
Shares of Eli Lilly (LLY) are up almost 18% and optimism remains high after a recent study revealed the pharma giant’s diabetes drug cut the risk of heart related deaths.
Select the service that is right for you!COMPARE ALL SERVICES
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas